Key Highlights

• Press release detailing the BLA submission was attached as Exhibit 99.1.

• Slide presentation for the investor call was filed as Exhibit 99.2.

• On June 29, 2026 Larimar announced accelerated‑approval filing and disclosed positive open‑label results in Friedreich’s ataxia.

Larimar Therapeutics Inc. (NASDAQ: LRMR) disclosed a dual milestone on June 29, 2026: the submission of the first module of its rolling Biologics License Application (BLA) for the experimental therapy nomlabofusp, and the release of encouraging data from a long‑term open‑label study in patients with Friedreich’s ataxia. Both announcements were made in a formal press release and an accompanying slide deck.

Regulatory Submission

The company filed the initial BLA module with the U.S. Food and Drug Administration, seeking accelerated approval for nomlabofusp. The press release containing this regulatory update was attached as Exhibit 99.1, underscoring Larimar’s compliance with filing requirements.

Clinical Data

Parallel to the regulatory filing, Larimar reported positive outcomes from its ongoing open‑label study of daily subcutaneous nomlabofusp in adolescent and adult Friedreich’s ataxia patients. The study’s results, described as encouraging, add clinical support to the accelerated‑approval pathway.

Investor Call Details

Larimar scheduled a conference call for June 29, 2026 to discuss the regulatory progress and the new data. The slide presentation used during the call was filed as Exhibit 99.2, providing investors with visual detail on the BLA status and trial findings.

Compliance and Reporting

The disclosures were made in a Form 8‑K filing, consistent with the Securities Exchange Act of 1934. The filing includes the press release and presentation as exhibits, meeting the SEC’s transparency standards for material developments.

Market Context

Larimar’s inclusion in the Russell 2000 Growth Benchmark highlights its relevance among growth‑oriented small‑cap stocks. The combined regulatory and clinical milestones position the company for potential market revaluation, contingent on FDA review outcomes.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.